MediumEndocrinologyUse of SGLT2 inhibitors in type 2 diabetes with CVD/CKDau-racpau-amc
A 64-year-old man with type 2 diabetes, chronic kidney disease (eGFR 45 mL/min/1.73 m²) and prior myocardial infarction has HbA1c 7.6% (60 mmol/mol) despite metformin and a DPP‑4 inhibitor. According to Australian recommendations, which additional agent is preferred to improve both glycaemic control and cardiorenal outcomes?